Explore More Than Just This Free Article

This article is a glimpse of the exclusive insights we provide daily to industry leaders. Dive deeper into our industry-specific reports and uncover the strategic information you need.

Industry Intelligence needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

New NOSOSENS project tests bio-based disinfectant designed to reduce hospital-acquired infections with portable biosensor platform; Hospital General Universitario de Valencia partners with AIMPLAS, Química Deambla-Rogemar, CrespoPrinting Group and AGC

Valencia , October 3, 2024 (press release) –

The developments will be tested at Hospital General Universitario de Valencia, which participates in the NOSOSENS project through its research foundation, together with AIMPLAS, Química Deambla-Rogemar, CrespoPrinting Group and Assessoria de Gestió i Comunicacions (AGC).

The aim of these new solutions is to reduce deaths caused by drug-resistant infections acquired in hospital settings, which could reach 10 million worldwide by 2050.

According to data from the European Centre for DiseasePrevention and Control, approximately 4 million patients acquire a healthcare-associated infection (HAI) or nosocomial infection each year in the European Union and approximately 37,000 deaths are the direct result of these infections, making them a major cause of mortality. Infectious microorganisms acquired in hospitals are often resistant to many common antibiotics. By 2050, the number of deaths caused by drug-resistant infections is expected to increase to 10 million worldwide, thus posing a serious public health problem.

Early detection of nosocomial infections and effective disinfection of hospitals and healthcare centres are key to reducing these figures, but the methods currently used have their limitations. Hence the creation of the NOSOSENS Project, which is working on a new bio-based disinfectant designed to eliminate the main pathogens on a new, flexible and portable biosensor platform. It uses printed electrochemical sensors for rapid, selective detection of Staphylococcus aureus, which is resistant to methicillin and responsible for 11% of nosocomial infections.

The Fundación de Investigación Hospital General Universitario de Valencia, the PlasticsTechnology Centre (AIMPLAS), the companies Química Deambla-Rogemar and CrespoPrinting Group, coordinated by the Assessoria de Gestió y Comunicacions (AGC), are collaborating on this research project funded by the Valencian Institute for Competitiveness and Innovation (IVACE+i) through the call for Strategic Projects in Cooperation 2023 of the Valencian Innovation Agency in conjunction with the ERDFProgramme.
 

Immediate test and environmentally friendly disinfectant

The diagnostic method par excellence currently used in hospitals for the prevention of nosocomial diseases involves the detection of pathogens by means of cell culturemicroscopy on a monthly basis. The results become available in four to five days on average. The new portable electrochemical biosensor platform from NOSOSENS provides immediate specific detection and quantification of bacteria from the Staphylococcus aureus family. It will also include a monitoring, management and display system for data and alerts.

The current problem with cleaning products is that pathogens’ antimicrobial resistancemakes disinfectant solutions less effective Stronger disinfectants such as peracetic acidmust therefore be used, though it causes long-term damage to surfaces and cannot beincluded in daily cleaning protocols in healthcare facilities. The solution proposed by NOSOSENS has a high biocidal potential, but is biobased and biodegradable, making it less aggressive and more environmentally friendly.

Both innovations will be tested at Hospital General Universitario de Valencia, which will be equipped with a portable, easy-to-use early detection system for healthcare personnel to test for this type of bacteria, as well as an effective and sustainable pathogen elimination system for surgical elements and areas. Synergies with the sensorization platform will optimize disinfection processes for safety against hospital-acquired infections. This system will make it possible to trace and control the infectious agent and take rapid action to eliminate surface colonization, as necessary, thus minimizing the risks associated with hospital stays.

About AIMPLAS

At AIMPLAS, the Plastics Technology Centre, we have a twofold mission: to provide added value to companies so they can create wealth and quality employment, and to meet societal challenges to improve people’s quality of life and ensure environmental sustainability.

We are a non-profit research association and member of REDIT (Network ofTechnological Institutes of the Valencia Region) offering enterprises in the plastics industry comprehensive and customized solutions, including development and innovation projects, training, competitive and strategic intelligence, and technological services suchas analysis, testing and technical assistance.

We also support the 17 SDGs of the UN Global Compact when carrying out our work and corporate social responsibility activities.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo with Dan
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.